Company intelligence / Profile preview

Agen Biomedical

Acacia Ridge, Queensland, Australiamaterresearch.org.au ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Agen Biomedical developed ThromboView®, an anti-fibrin humanized monoclonal antibody Fab' fragment labeled with technetium‑99m for SPECT imaging to detect acute pulmonary embolism. Two FDA Phase II trials in the US were completed, demonstrating clinical progress in non-invasive blood clot diagnostics. The company also collaborates on hepatitis B therapeutics validation in China through its Shanghai subsidiary and academic partners.

Therapeutic areas: Infectious DiseasesCardiovascular
Modalities: Monoclonal antibodyAntibody fragmentDiagnostic agent (radiolabeled antibody fragment)
Industry: Protein Biomarker Diagnostics

Partnerships

Academy of Military Medical Sciences, Beijing (hepatitis B drug validation)

Beyond the preview

Go deeper on Agen Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agen Biomedical.

Explore the full profile